Fate Therapeutics (FATE) Accumulated Expenses (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Accumulated Expenses data on file, last reported at $13.6 million in Q1 2026.

• Quarterly Accumulated Expenses fell 20.75% year-over-year to $13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.6 million (down 20.75% YoY) and the FY2025 annual result came in at $20.0 million, up 106.22% from the prior year.
• Accumulated Expenses retreated to $13.6 million in Q1 2026, from $20.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $53.9 million in Q4 2022 to a low of $5.4 million in Q1 2024.
• A 5-year average of $20.4 million and a median of $17.4 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 319.32% — and 2024, when it sank 82.82%.
• Tracing FATE's Accumulated Expenses over 5 years: stood at $53.9 million in 2022, then sank by 48.98% to $27.5 million in 2023, then plunged by 64.71% to $9.7 million in 2024, then soared by 106.22% to $20.0 million in 2025, then slumped by 31.87% to $13.6 million in 2026.
• The last three Accumulated Expenses figures came in at $13.6 million (Q1 2026), $20.0 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.